gernguy you are the man and that was an excellent post. Looking forward to what you say in the future.
Hey gernguy23, I was the subject of your corrective post but I did not give a thumbs up or down. Perhaps others thought that to start out your sentence with a pejorative “Idiot” was NOT an indication of a post that was not trying to be rude. Most likely, some of the thumbs down were for perceived arrogance.
Most investors here, despite, many with science backgrounds are not familiar with pharmacological manufacturing practices so thanks for the clarification. After researching this subject you are totally correct in that MedKoo is a reference standard type company and to clarify for those like myself without your background, Drug reference Standards are highly characterized physical specimens used in testing by pharmaceutical and related industries to help ensure the identity, strength, quality, and purity of medicines.
Good manufacturing practices (GMP) are the practices required in order to conform to guidelines recommended by agencies that control authorization and licensing for manufacture and sale of food, drug products, and active pharmaceutical products.
Now since you appear, at least lexically, to be an expert on drug manufacturing how about sharing that knowledge in regards to Imetelstat. What would be a typical cost to manufacture this type of drug? Who or what company would be most likely to do that? Is the manufacture of Imetelstat beyond Geron’s ability? Helping us understand that would be much more interesting than reading about how many thumbs up or down you got!
Since you deal in the pejorative.
Also from MedKoo website they list their products in human clinical trials and they sell approved anticancer agents used by pharmaceutical companies.
Clinical Trial Part 4 (FA-KZ)
Cat# || Product name
201490 || HMN-214 (PLK-1 inhibitor)
205486 || HQK-1004
205487 || HSP-990 (HSP inhibitor)
205735 || Hycanthone (Topoisomerase inhibitor, DNA intercalator)
201495 || Hypothemycin
205879 || Laniquidar (R101933) (Oral P-glycoprotein Inhibitor)
202171 || Ibrutinib (PCI-32765) (BTK inhibitor)
201684 || Ibutamoren
205847 || Icotinib (EGFR inhibitor)
205880 || Idoxifene (estrogen antagonist)
205489 || Imetelstat (GRN-163L)
201500 || Imexon (caspase inhibitor)
205886 || IMMU-132 (antibody-SN38 conjugate)
B_splash. After I found Medkoo, which lists Imetestat it appears to be a Chinese company with an office in the US. So credibility is somewhat suspect and I still have no idea if Geron ever had dealings with MedKoo; but since MedKoo was founded in 2009, which is much later than the first Clinical trial of Imetelstat in 2005, I doubt it!
The founder Quingqi Chen has written some literature on cancer but I don't understand 本书是全球首部研究抗癌药物分子库的专业工具书，全书根据抗癌药物作用机制归类，系统地介绍了人类历史上已知的抗癌化合物，包括世界各国已经获准上市的抗癌药物，正在临床研究中的抗癌候选药物，正在临床前研完阶段的抗癌化合物、
Do Beavers read Mandarin?
Yes indeed I again bought today because the Mayo MF study hold was released. Prior to the Geron hold the planned Imetelstat Phase II trial was to be launched across the Globe in twenty cities. Starting in Israel, Italy, Canada and 20 plus centers in the USA including CA, NY and the Southern part of the United States as well as the Mayo Clinic.
Geron hopefully is getting all its ducks in a row to launch this Phase II Trial as soon as possible, once the hold is released. There should be massive media attention for the Imetelstat FDA hold release and the Trial start.
Both MF patients and Geron Investors need a complete remission!
Little info out there Black but I found MedKoo Biosciences which is a supplier of anticancer chemical reagents and kinase inhibitors. They make, sell and distribute anticancer small molecule reagents for oncology research and one of their products is Imetelstat. I have no idea if Geron gets their supply of Imetelstat from MedKoo or not or what costs are involved.
Medkoo? LoL what a name! Here is info from their website.
""""MedKoo product information:
Description of Imetelstat sodium: Imetelstat sodium, the sodium salt of imetelstat, is a telomerase inhibitor, also a synthetic lipid-conjugated, 13-mer oligonucleotide N3' P5'-thio-phosphoramidate with potential antineoplastic activity. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis
Current developer: Geron.
Availability and price:
This agent is not in stock, which may be available through custom synthesis.""""'
I've heard of that and an investigation by the Washington Monthly and the British Medical Journal has found in the recent past that at least four members of a FDA advisory board which voted to approve a drug used in birth control pills had either done work for the drugs' manufacturer or received research funds from the manufacturer.
Though the four committee members disclosed their ties to the FDA, the FDA decided that the ties did not matter and did not make the disclosures public. Tragically, the drug the committee endorsed have caused loss of life to some if the women who took them.
Looked up that info again under PubChem and found this.
Also known as: Motesanib; AMG-706; 453562-69-1; AMG 706; CHEBI:51098; N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
Molecular Formula: C22H23N5O Molecular Weight: 373.45092 InChIKey: RAHBGWKEPAQNFF-UHFFFAOYSA-N
Mruyog your suggestion is being trivialized by most but let's consider Tesla Motors and the CEO compensation of Mr. Elon Musk who has a total annual compensation of $69,989. Musk obviously believes in Tesla and is willing to put short term gain aside for the benefit of his company and shareholders.
Good grief you are like 50 times worse than blackmarango. Indeed, if a direct mental comparison was made Black would = Einstein and the other alternative would = a cockroach.
Black, thanks for the reply. If I remember correctly during one of those (disastrous for investors) conference calls Scarlett even said something to the effect that INCY is not the enemy. My worry is that even in the event that any supposed negotiations are taking place between INCY and Geron:: would be that INCY would still gain by having the PPS down where it is now.
In the event of any sale of Geron, Scarlett and the Board would make out like bandits but us shareholders would still be at the bottom of the list. Still any whiff of a sale would send the PPS dramatically upwards. I don't think anything like this would happen till well into the future when (hopefully) IMET Phase two is underway. So perhaps Scarlett might be keeping things friendly with INCY for negotiation purposes.
My greatest wish now is for the end of the hold and that the danmnmn Phase II to finally start. Confirmations of CR or PR by this Geron trial would go a long way to convincing fence sitting investors that IMET is the real deal.
Black, do you think Scarlett is trying not to annoy INCY in the hopes that he can work a deal with them?
Chippy had the "Nads" of Tesla's Musk he would time the Asterias distribution for Tuesday and then simultaneously announce on Tuesday both the full reversal of the FDA clinical hold and the Start of the Phase II Myelofibrosis Imetelstat trial.
Sentiment: Strong Buy
I found Asterias Biotherapeutics Inc listed in TD Ameritrade as an OTCBB: with the stock symbol AHRBV.
I have not received the spin-off shares yet but at least Asterias now is recognized by this broker. LOL the bid is 0.01 and the ask is $100. No volume. The shares out are 6.5 million.
The easily found FDA Protocol about contacting a company and trying to resolve the issue BEFORE issuing a hold is exactly the point I brought up 4 months ago. Some here have incorrectly and pitifully implied that the initial FDA Hold notice phone call to Scarlett was the pre-hold resolution attempt.
Also, considering that the ET & PV trials were mainly completed and that patients would have to be contacted again for further testing... I correctly surmised that the Hold would be in place for at least 4 months.
The future of Imetelstat is almost certainly assured due to the complete responses for Myelofibrosis but the dunderheads running the company have placed the timetable for getting Imetelstat to patients that need it at real risk as well as sabotaging investor capital and confidence.
With the aging population needing robotic home assistance, tech savvy youth demanding the latest in robotic technology, surging medical costs controlled by telemedicine robots, world business facilitated by tele-presence meetings and 3D printing, and continued escalation of world military tensions coupled with terrorists threats, and the increased need for police, nuclear, and heavy industry to use robotics to probe situations too dangerous for first contact with humans..... IRobot will exponentially surge and quickly obtain a market cap challenging stock company leaders of today. Skeptical? so were most Google investors not that long ago.
Sentiment: Strong Buy